FDA File Acceptance for FYB202

Another step towards providing a high-quality, safe and affordable treatment…


EMA submission for biosimilar candidate FYB203 (Aflibercept)

"Our latest MAA submission once again demonstrates the high performance and…


Deutsches Eigenkapitalforum – we are attending!

We are very much looking forward to the "Deutsches Eigenkapitalforum" (Equity…


Global Biosimilars Week 2023

Global Biosimilars Week 2023 highlights the strong impact of biosimilars once…


Formycon publishes Q3 figures

Formycon's corporate development is reflected in the very positive Q3 figures…


Dr. Stefan Glombitza at the Lupus Alpha Investment Focus 2024

Formycon CEO Dr. Stefan Glombitza spoke at the Lupus Alpha Investment Focus…


Biosimilars: efficative, safe cost-efficient.

Read how Formycon is making an important contribution to improve patient access…